ARCUTIS BIOTHERAPEUTICS, INC. Increase (Decrease) in Inventories
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Increase (Decrease) in Inventories of $15.76 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in inventories for the quarter ending 2026-06-30 was $1.18M.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in inventories for the quarter ending 2026-03-31 was $14.58M, a 647.26% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in inventories for the quarter ending 2025-12-31 was $5.00K, a 98.11% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in inventories for the quarter ending 2025-09-30 was $5.89M.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in inventories for fiscal 2025 was $7.33M, a 1732.25% increase from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in inventories for fiscal 2024 was $400.00K, a 92.88% decline from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in inventories for fiscal 2023 was $5.62M, a 25.21% decline from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in inventories for fiscal 2022 was $7.51M.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $15.76M 10-Q · filed 2026-08-05 | $15.76M derived: sum of 3 quarters · filed 2026-08-05 | $21.65M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $14.58M 10-Q · filed 2026-05-06 | $14.58M derived: sum of 2 quarters · filed 2026-05-06 | $20.48M derived: sum of 3 quarters · filed 2026-05-06 | $19.96M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $5.90M derived: sum of 2 quarters · filed 2026-02-25 | $5.38M derived: sum of 3 quarters · filed 2026-08-05 | $7.33M 10-K · filed 2026-02-25 |
| 2025-09-30 | $5.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $5.37M derived: sum of 2 quarters · filed 2026-08-05 | $7.32M 10-Q · filed 2025-10-28 | $7.59M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$518.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.43M 10-Q · filed 2026-08-05 | $1.70M derived: sum of 3 quarters · filed 2026-08-05 | $1.09M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.95M 10-Q · filed 2026-05-06 | $2.22M derived: sum of 2 quarters · filed 2026-05-06 | $1.60M derived: sum of 3 quarters · filed 2026-05-06 | $2.24M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $265.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$346.00K derived: sum of 2 quarters · filed 2026-02-25 | $287.00K derived: sum of 3 quarters · filed 2026-02-25 | $400.00K 10-K · filed 2026-02-25 |
| 2024-09-30 | -$611.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $22.00K derived: sum of 2 quarters · filed 2025-10-28 | $135.00K 10-Q · filed 2025-10-28 | -$644.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $633.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $746.00K 10-Q · filed 2025-08-06 | -$33.00K derived: sum of 3 quarters · filed 2026-02-25 | $3.41M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $113.00K 10-Q · filed 2025-05-06 | -$666.00K derived: sum of 2 quarters · filed 2026-02-25 | $2.77M derived: sum of 3 quarters · filed 2026-02-25 | $4.70M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | -$779.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $2.66M derived: sum of 2 quarters · filed 2026-02-25 | $4.58M derived: sum of 3 quarters · filed 2026-02-25 | $5.62M 10-K · filed 2026-02-25 |
| 2023-09-30 | $3.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $5.36M derived: sum of 2 quarters · filed 2024-11-06 | $6.40M 10-Q · filed 2024-11-06 | $9.61M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $1.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $2.96M 10-Q · filed 2024-08-14 | $6.17M derived: sum of 3 quarters · filed 2025-02-25 | $10.47M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $1.04M 10-Q · filed 2024-05-14 | $4.24M derived: sum of 2 quarters · filed 2025-02-25 | $8.55M derived: sum of 3 quarters · filed 2025-02-25 | $8.55M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $3.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $7.51M derived: sum of 2 quarters · filed 2025-02-25 | $7.51M derived: sum of 3 quarters · filed 2025-02-25 | $7.51M 10-K · filed 2025-02-25 |
| 2022-09-30 | $4.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $4.31M derived: sum of 2 quarters · filed 2023-11-03 | $4.31M 10-Q · filed 2023-11-03 | $4.31M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | $0.00 derived: sum of 3 quarters · filed 2024-02-27 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | $0.00 derived: sum of 2 quarters · filed 2024-02-27 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $0.00 10-K · filed 2024-02-27 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |